demonstrated clinically meaningful

Related by string. * demon strated . demon strating . Demonstrating : demonstrating knives mops . demonstrated statistically significant . XIENCE V demonstrated / Clinically : patented clinically proven . clinically localized prostate . clinically obese / MEANINGFUL . Meaningful : clinically meaningful improvement . clinically meaningful improvements . Meaningful Use * *

Related by context. Frequent words. (Click for all words.) 73 Secondary endpoints include 70 Secondary endpoints included 68 demonstrated statistically significant 65 analgesic efficacy 65 teriflunomide 64 pharmacokinetic PK 64 ADAS cog 63 Psoriasis Area 63 achieved statistical significance 63 paclitaxel eluting stents 63 Randomized controlled 63 Secondary endpoints 63 CIMZIA TM 62 pharmacokinetic profiles 62 nonrandomized 62 mg QD 62 administered subcutaneously 62 #mg/day [001] 62 APTIVUS 62 Pegasys ® 62 tolvaptan 62 Pharmacokinetic 62 mucosal healing 62 plus methotrexate 62 platelet reactivity 62 adalimumab 61 pharmacokinetics PK 61 XIENCE V demonstrated 61 receiving VELCADE 61 lipid parameters 61 secondary efficacy endpoints 61 Golimumab 61 Montgomery Asberg Depression 61 efficacy tolerability 61 liposomal formulation 61 pharmacodynamic effects 60 prospectively defined 60 plus prednisone 60 plus MTX 60 intracoronary 60 NLX P# 60 Unified Parkinson Disease 60 clinically meaningful 60 certolizumab pegol 60 alteplase 60 6R BH4 60 lispro 60 INCB# [001] 60 mg BID 60 tocilizumab 60 retinal thickness 60 Thrombolysis 60 Adalimumab 60 ACR# response 60 Tolerability 60 lanthanum carbonate 59 decitabine 59 forodesine 59 pharmacokinetic parameters 59 Alzheimer Disease Assessment 59 Natalizumab 59 virologic response 59 relapsing multiple sclerosis 59 PEGPH# 59 ketorolac 59 prospective randomized controlled 59 Pivotal Phase III 59 PTNS 59 tiotropium 59 fasting plasma glucose 59 prespecified 59 statistically significant p = 59 UPDRS 59 PANSS 59 secondary endpoint 59 ARIKACE 59 ACZ# 59 extrapyramidal symptoms 59 eszopiclone 59 metabolic parameters 59 locoregional 59 chemoradiotherapy 59 QTc 59 posttreatment 58 follicular NHL 58 sustained virological response 58 TYGACIL 58 Fidaxomicin 58 Dasatinib 58 daunorubicin 58 T2DM 58 AZX# 58 therapeutic regimens 58 risedronate 58 TAXUS Stent 58 Cloretazine R VNP#M 58 sipuleucel T 58 Traficet EN 58 virologic 58 plus dexamethasone 58 interpersonal psychotherapy

Back to home page